周一盘后，生物制药软件公司Certara（CERT）股价大涨5.25%，引发市场关注。
消息面上，投资银行杰富瑞大幅上调了Certara的目标价，从12.50美元上调至14.50美元，涨幅达16%。这一积极的分析师评级调整成为推动Certara股价上涨的主要因素。
Certara是一家专注于生物制药领域的软件公司，为药物开发和监管审批提供生物仿真和建模服务。分析师目标价的上调表明市场对公司未来发展前景持乐观态度，这可能反映出Certara在生物制药技术创新和市场拓展方面取得了积极进展。投资者对这一利好消息反应强烈，推动股价在盘后交易中显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.